Erectile Dysfunction Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Erectile Dysfunction Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Erectile Dysfunction Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ED therapeutics market. The report identifies the key trends shaping and driving the global ED therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ED therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the Erectile Dysfunction(ED) therapeutics market was valued at $2,890m in 2010, and is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.2% over the next eight years, to reach $2,625m by 2018. The decline in the market is primarily due to the patent expiry of Cialis in 2017 and Levitra in 2018. However GlobalData’s analysis suggests that the global ED therapeutics market grew at a CAGR of 3.4%, from $2,448m in 2005 to $2,890m in 2010. The growth in the market between 2005 and 2010 was attributed to the increasing elderly population and expected launch of avanafil in 2013 in the US.

Scope

The report provides information on the key drivers and challenges of the ED therapeutics market. Its scope includes -
- Annualized market revenues data for seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for ED therapeutics from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as PDE5 inhibitor, vasodilator, a1 adrenergic receptor antagonist, VPAC2 agonist, Melatonin receptor agonist, estrogen receptor antagonist, gene therapy, dopamine agonist and genito-urinary agent.
- Analysis of the current and future competition in the seven key countries for the ED therapeutics market. Key market players covered are VIVUS /Mitsubishi Tanabe, Apricus Bio, Plethora Solutions Holdings, and Warner Chilcott Plc/Dong-A Pharm.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ED therapeutics market.
- Analysis of key recent licensing and partnership agreements in the ED therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ED therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ED market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ED market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Erectile Dysfunction Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Worldwide Prevalence
2.2.2 The US
2.2.3 The UK
2.2.4 Germany
2.2.5 France
2.2.6 Italy
2.2.7 Spain
2.2.8 Japan
2.2.9 Quality of Life (QoL)
2.3 Etiology
2.4 Pathophysiology
2.4.1 Psychogenic
2.4.2 Neurogenic
2.4.3 Endocrinologic
2.4.4 Arteriogenic
2.4.5 Cavernosal (venogenic)
2.4.6 Fibroelastic Component
2.4.7 Smooth Muscle
2.4.8 Gap Junction
2.4.9 Endothelium
2.5 Signs and Symptoms
2.6 Diagnosis
2.6.1 Initial Assessment
2.6.2 Physical Examinations
2.6.3 Laboratory Testing
2.6.4 Cardiovascular System
2.6.5 Specialized Investigations
2.6.6 Penile Abnormalities
2.7 Treatment and Management Options
2.7.1 Hypogonadism and Testosterone Replacement Therapy
2.7.2 First - line Treatment
2.7.3 Second - line Treatment
2.7.4 Third - line Treatment
2.7.5 Lifestyle Management
2.7.6 Patient/Partner Education - Consultation and Referrals
2.8 Referral Pathway
2.9 GlobalData Pipeline Report Guidance
3 ED Therapeutics - Market Characterization
3.1 ED Therapeutics Market Size (2005 - 2010) - Global
3.2 ED Therapeutics Market Forecast (2010 - 2018) - Global
3.3 ED Therapeutics Market Size (2005 - 2010) - The US
3.4 ED Therapeutics Market Forecast (2010 - 2018) - The US
3.5 ED Therapeutics Market Size (2005 - 2010) - France
3.6 ED Therapeutics Market Forecast (2010 - 2018) - France
3.7 ED Therapeutics Market Size (2005 - 2010) - Germany
3.8 ED Therapeutics Market Forecast (2010 - 2018) - Germany
3.9 ED Therapeutics Market Size (2005 - 2010) - Italy
3.10 ED Therapeutics Market Forecast (2010 - 2018) - Italy
3.11 ED Therapeutics Market Size (2005 - 2010) - Spain
3.12 ED Therapeutics Market Forecast (2010 - 2018) - Spain
3.13 ED Therapeutics Market Size (2005 - 2010) - The UK
3.14 ED Therapeutics Market Forecast (2010 - 2018) - The UK
3.15 ED Therapeutics Market Size (2005 - 2010) - Japan
3.16 ED Therapeutics Market Forecast (2010 - 2018) - Japan
3.17 Drivers and Barriers for the ED Therapeutics Market
3.17.1 Drivers for the ED Therapeutics Market
3.17.2 Barriers for the ED Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 ED Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Erectile Dysfunction Therapeutics Market
4.3.1 Viagra (sildenafil citrate)
4.3.2 Cialis (tadalafil)
4.3.3 Levitra (vardenafil hydrochloride)
4.3.4 MUSE (alprostadil urethral suppository)
4.3.5 Caverject (alprostadil for injection)
4.3.6 CaverJect Impulse (dual chamber system alprostadil for injection)
4.4 Key Takeaway
5 ED Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 ED Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 ED Therapeutics - Filed Pipeline
5.3.2 ED Therapeutics - Phase III Pipeline
5.3.3 ED Therapeutics - Phase II Pipeline
5.3.4 ED Therapeutics - Phase I / Phase II Pipeline
5.3.5 ED Therapeutics - Phase I Pipeline
5.3.6 ED Therapeutics Market - Pre - clinical Pipeline
5.3.7 ED Therapeutics Market - Discovery Pipeline
5.3.8 Technology Trends Analytic Framework
5.4 ED Therapeutics Market - Pipeline by Mechanism of Action
5.5 ED Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Avanafil
5.6.2 Vitaros (alprostadil cream)
5.6.3 Invicorp
5.6.4 WC3043 (udenafil)
5.7 Key Takeaway
6 ED Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in ED Therapeutics Clinical Trials
7 ED Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 ED Therapeutics - Implications for Future Market Competition
8 ED Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.3 VIVUS
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 ED Pipeline Product
8.4 Apricus Bio
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 ED Pipeline Product
8.5 Plethora Solutions Holdings
8.5.1 Overview
8.5.2 Financial Performance
8.5.3 ED Pipeline Product
8.6 Warner Chilcott
8.6.1 Overview
8.6.2 Financial Performance
8.6.3 ED Pipeline Product
9 ED Therapeutics - Licensing and Partnership Deals
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Epidemiology - based Forecasting
10.3.5 Primary Research
10.3.6 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: ED Management Algorithm According to Graded Cardiovascular Risk, 2009
Table 2: ED Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 3: ED Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Table 4: ED Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 5: ED Therapeutics Market, The US, Forecasts ($m), 2010 - 2018
Table 6: ED Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 7: ED Therapeutics Market, France, Forecasts ($m), 2010 - 2018
Table 8: ED Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 9: ED Therapeutics Market, Germany, Forecasts ($m), 2010 - 2018
Table 10: ED Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 11: ED Therapeutics Market, Italy, Forecasts ($m), 2010 - 2018
Table 12: ED Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 13: ED Therapeutics Market, Spain, Forecasts ($m), 2010 - 2018
Table 14: ED Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 15: ED Therapeutics Market, The UK, Forecasts ($m), 2010 - 2018
Table 16: ED Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 17: ED Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018
Table 18: Adverse Events Reported by =2% of Patients Treated with Viagra and a Placebo in PRN Flexible - Dose Phase II/III Studies
Table 19: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Primary Clinical Trials of Cialis in the US.
Table 20: Mean Endpoint and Change from Baseline for the EF Domain of the IIEF in the General ED Population in Five Primary Trials Outside the US
Table 21: Mean Post - Baseline Success Rate and Change from Baseline for SEP Question 2 in the General ED Population in Five Pivotal Trials Outside the US
Table 22: Mean Post - Baseline Success Rate and Change from Baseline for SEP Question 3 in the General ED Population in Five Pivotal Trials Outside the US
Table 23: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in ED Patients with Diabetes
Table 24: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in Patients who Developed ED Following Bilateral Nerve - Sparing Radical Prostatectomy
Table 25: Percentage of Patients Reporting Successful Erections Within 30 Minutes of Dosing
Table 26: Clinical Trial Results to Determine the Optimal Use of Cialis
Table 27: Clinical Trial Results to Determine the Optimal Use of Cialis
Table 28: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Cialis for Once Daily Use Studies
Table 29: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Cialis for Once Daily Use Study in ED Patients with Diabetes
Table 30: Treatment - Emergent Adverse Events Reported by =2% of Patients Treated with Cialis 10mg or Cialis 20mg in the Eight Primary Placebo - Controlled Phase III Studies-- for Cialis for Use as Needed
Table 31: Treatment - Emergent Adverse Events Reported by =2% of ED Patients Treated with Cialis 2.5mg or Cialis 5mg for Once Daily Use in the Three Primary Placebo - Controlled Phase III Studies at 12 Weeks-
Table 32: Treatment - Emergent Adverse Events Reported by =2% of Patients Treated with Cialis 2.5mg or Cialis 5mg for Once Daily Use in One Placebo - Controlled Phase III Study-
Table 33: Efficacy of Levitra in a General ED Population
Table 34: Efficacy of Levitra in ED Patients with Diabetes Mellitus
Table 35: Efficacy of Levitra in ED Patients After Radical Prostatectomy
Table 36: Adverse Events Reported by =2% of Patients Treated with Levitra in Fixed and Flexibley Dose Randomized, Controlled Clinical Trials of Levitra 5mg, 10mg, or 20mg.
Table 37: Adverse Drug Reactions of MUSE During In - Clinic Titration
Table 38: Adverse Events Reported by =2% of ED Patients Treated with MUSE at Home in Phase III Placebo - Controlled Clinical Trials for up to Three Months
Table 39: Local Adverse Reactions Reported by =1% of ED Patients Treated with Caverject Injection for up to 18 Months-
Table 40: Systemic Adverse Events Reported by =1% of ED Patients Treated with Caverject Injection for up to 18 Months-
Table 41: ED Therapeutics, Filed Pipeline, 2011
Table 42: ED Therapeutics, Phase III Pipeline, 2011
Table 43: ED Therapeutics, Phase II Pipeline, 2011
Table 44: ED Therapeutics, Phase I / Phase II Pipeline, 2011
Table 45: ED Therapeutics, Phase I Pipeline, 2011
Table 46: ED Therapeutics, Pre - clinical Pipeline, 2011
Table 47: ED Therapeutics, Discovery, 2011
Table 48: ED Therapeutics, Most Promising Drugs Under Clinical Development, 2011
Table 49: REVIVE Studies Results of avanafil
Table 50: REVIVE - Diabetes Studies Results of avanafil
Table 51: Efficacy Data of Invicorp
Table 52: Safety Data of Invicorp
Table 53: ED Therapeutics Market, Clinical Trials by Country, 2011
Table 54: ED Therapeutics Market Therapeutics, Clinical Trials by Phase, 2011
Table 55: ED Therapeutics, Clinical Trials by Status, 2011
Table 56: ED Therapeutics, Prominent Sponsors, 2011
Table 57: ED Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 58: VIVUS, ED Pipeline Products, 2011
Table 59: Apricus Bio, ED Pipeline Products, 2011
Table 60: Plethora Solutions Holdings, ED Pipeline Products, 2011
Table 61: Warner Chilcott, ED Pipeline Products, 2011
Table 62: ED Therapeutics, Global, Deals, 2009 - 2011

1.2 List of Figures
Figure 1: Classification of Erectile Dysfunction
Figure 2: Schematic Representation of Central and Intracavernosal Mechanisms Involved in the Control of Penile Erection
Figure 3: Etiology of Erectile Dysfunction
Figure 4: Treatment Algorithm for Androgen Therapy in a Man Presenting with ED
Figure 5: Management Algorithm According to Graded Cardiovascular Risk, 2009.
Figure 6: ED Referral Pathway 2011
Figure 7: ED Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 8: ED Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 9: ED Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 10: ED Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 11: ED Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 12: ED Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 13: ED Therapeutics Market, Germany , Revenue ($m), 2005 - 2010
Figure 14: ED Therapeutics Market, Germany , Forecast ($m), 2010 - 2018
Figure 15: ED Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 16: ED Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 17: ED Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 18: ED Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 19: ED Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 20: ED Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 21: ED Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 22: ED Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 23: Opportunity and Unmet Need in the ED Therapeutics Market, 2010
Figure 24: ED Therapeutics, Strategic Competitor Assessment, 2011
Figure 25: ED Therapeutics, Pipeline by Phase of Development, 2011
Figure 26: ED Therapeutics, Technology Trends Analytics Framework, 2011
Figure 27: ED Therapeutics, Technology Trends Analytics Framework - Description, 2011
Figure 28: ED Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 29: Erectile Dysfunction Therapeutics, Molecular Structure of avanafil
Figure 30: ED Therapeutics Market, Clinical Trials by Country, 2011
Figure 31: ED Therapeutics, Clinical Trials by Phase, 2011
Figure 32: ED Therapeutics, Clinical Trials by Status, 2011
Figure 33: ED Therapeutics Market, Overall Sponsors, 2011
Figure 34: ED Therapeutics, Prominent Sponsors, 2011
Figure 35: ED Therapeutics Market, Drivers and Restraints, 2011
Figure 36: Implications for Future Market Competition in the ED Market, 2011
Figure 37: ED Therapeutics Market, Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Erectile Dysfunction Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ED therapeutics market. The report identifies the key trends shaping and driving the global ED therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ED therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
ED Therapeutics Market is Forecast to Show a Negative Growth by 2018

GlobalData estimates that the Erectile Dysfunction (ED) therapeutics market was valued at $2,890m in 2010, and is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.2% over the next eight years, to reach $2,625m by 2018. The projected decline in the market is primarily due to the patent expiry of Cialis in 2017 and Levitra in 2018. However GlobalData’s analysis suggests that the global ED therapeutics market grew at a CAGR of 3.4%, from $2,448m in 2005 to $2,890m in 2010. The growth in the market between 2005 and 2010 was attributed to the increasing elderly population and the expected launch of avanafil in 2013 in the US.

ED Therapeutics Market, Global, Market Revenue ($m), 2005 - 2018

Source: GlobalData, Selvin E, et al., Prevalence and risk factors for erectile dysfunction in the US. The American Journal of Medicine 2007. Litwin MS, et al., Urologic Diseases in America 2007.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC), the US. James A Kaye, et al. Incidence of erectile dysfunction and characteristics of patients before and after the introduction of sildenafil in the United Kingdom: cross sectional study with comparison patients. British Medical Journal (BMJ) 2003; 326:424 - 5.

Current Treatment Options Leave a Low Level of Unmet Need

GlobalData found that the available treatment options are successful in meeting the market demand. There is a low unmet need in the ED therapeutics market. The low unmet need shows that the market is well served by the currently available products. There are six approved products in the market for ED - Viagra, Cialis, Levitra, MUSE, Caverject injection and CaverJect Impulse. The low unmet need can be fulfilled only by products offering better efficacy and safety profiles with a low cost of therapy.

VIVUS
Apricus Bio
Plethora Solutions Holdings
Warner Chilcott